Open Access Green as soon as Postprint is submitted to ZB.
Ghrelin and LEAP-2: Rivals in energy metabolism.
Trends Pharmacol. Sci. 39, 685-694 (2018)
Liver-expressed antimicrobial peptide 2 (LEAP-2), the endogenous noncompetitive allosteric antagonist of the growth hormone secretagogue receptor 1a (GHSR1a), was recently identified as a key endocrine factor regulating systemic energy metabolism. This antagonist impairs the ability of ghrelin to activate GHSR1a and diminishes ghrelin-induced Ca2+ release in vitro. The physiological relevance of the molecular LEAP-2-GHSR1a interaction was subsequently demonstrated in vivo. LEAP-2 is therefore a promising therapeutic target in the treatment of obesity and other metabolic diseases. Here, we discuss not only the current understanding of LEAP-2 in metabolic regulation, but also the potential of this peptide in the treatment of obesity and other diseases that involve dysregulation of the ghrelin system.
Edit extra informations Login
Publication type Article: Journal article
Document type Review
Keywords Gh ; Ghsr1a ; Leap-2 ; Food Intake ; Ghrelin ; Metabolic Syndrome; Des-acyl Ghrelin; Hormone Secretagogue Receptor; Healthy Older-adults; Diet-induced Obesity; Growth-hormone; Food-intake; Double-blind; Weight-loss; Glucose-metabolism; Gastric Bypass
ISSN (print) / ISBN 0165-6147
Quellenangaben Volume: 39, Issue: 8, Pages: 685-694
Publisher Cell Press
Publishing Place Amsterdam
Reviewing status Peer reviewed
Institute(s) Institute of Diabetes and Obesity (IDO)